{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:33:07Z","timestamp":1777462387597,"version":"3.51.4"},"reference-count":54,"publisher":"Wiley","issue":"6b","license":[{"start":{"date-parts":[[2009,6,5]],"date-time":"2009-06-05T00:00:00Z","timestamp":1244160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cellular Molecular Medi"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although signalling through the type I insulin\u2010like growth factor receptor (IGF\u2010IR) maintains the survival of haematopoietic cells, a specific role of IGF\u2010IR in haematological neoplasms remains largely unknown. Chronic myeloid leukaemia (CML) is the most common subtype of chronic myeloproliferative diseases. Typically, CML evolves as a chronic phase (CP) disease that progresses into accelerated (AP) and blast phase (BP) stages. In this study, we show that IGF\u2010IR is universally expressed in four CML cell lines. IGF\u2010IR was expressed in only 30% and 25% of CP and AP patients, respectively, but its frequency of expression increased to 73% of BP patients. Increased expression levels of IGF\u2010IR with CML progression was supported by quantitative real\u2010time PCR that demonstrated significantly higher levels of IGF\u2010IR mRNA in BP patients. Inhibition of IGF\u2010IR decreased the viability and proliferation of CML cell lines and abrogated their growth in soft agar. Importantly, inhibition of IGF\u2010IR decreased the viability of cells resistant to imatinib mesylate including BaF3 cells transfected with p210 BCR\u2010ABL mutants, CML cell lines and primary neoplastic cells from patients. The negative effects of inhibition of IGF\u2010IR were attributable to apoptosis and cell cycle arrest due to alterations of downstream target proteins. Our findings suggest that IGF\u2010IR could represent a potential molecular target particularly for advanced stage or imatinib\u2010resistant cases.<\/jats:p>","DOI":"10.1111\/j.1582-4934.2009.00795.x","type":"journal-article","created":{"date-parts":[[2009,6,5]],"date-time":"2009-06-05T18:05:38Z","timestamp":1244225138000},"page":"1777-1792","source":"Crossref","is-referenced-by-count":17,"title":["Inhibition of IGF\u2010IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib\u2010resistant chronic myeloid leukaemia cells"],"prefix":"10.1111","volume":"14","author":[{"given":"Ping","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joya","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mate","family":"Gergely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Garcia\u2010Manero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph B.","family":"Arlinghaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hesham M.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,7,26]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1986.tb04528.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2184.1994.tb01406.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.23.11217"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00055-7"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M106673200"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-1448"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.36023"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.14.7263"},{"key":"e_1_2_6_10_2","first-page":"3353","article-title":"A dominant negative mutant of the insulin\u2010like growth factor\u2010I receptor inhibits the adhesion, invasion, and metastasis of breast cancer","volume":"58","author":"Dunn SE","year":"1998","journal-title":"Cancer Res."},{"key":"e_1_2_6_11_2","first-page":"7834","article-title":"Antitumor effects of a soluble insulin\u2010like growth factor I receptor in human ovarian cancer cells: advantage of recombinant protein administration in vivo","volume":"63","author":"Hongo A","year":"2003","journal-title":"Cancer Res."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700524"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.4.921.921"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0293"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0306"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2002.01525.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199907153410306"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3460176"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.11.4.1785"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-561"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.289.5486.1938"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1062538"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20922"},{"key":"e_1_2_6_26_2","first-page":"1213","article-title":"Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia","volume":"88","author":"Sureda A","year":"2003","journal-title":"Haematologica."},{"key":"e_1_2_6_27_2","first-page":"303","article-title":"Insulin\u2010like growth factor I (IGF\u2010I) and the IGF\u2010I receptor prevent etoposide\u2010induced apoptosis","volume":"55","author":"Sell C","year":"1995","journal-title":"Cancer Res."},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1361"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208065"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.2178"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-091769"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-020305"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3472"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00096-X"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0606509103"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2007.12.002"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2006-0001"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404217"},{"key":"e_1_2_6_39_2","first-page":"2243","article-title":"The insulin\u2010like growth factor 1 receptor is required for the proliferation of hemopoietic cells","volume":"7","author":"Reiss K","year":"1992","journal-title":"Oncogene."},{"key":"e_1_2_6_40_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.4340.4340","volume-title":"Guide to leukemia\u2010lymphoma cell lines","author":"Drexler HG","year":"2005"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403898"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602190"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-040022"},{"key":"e_1_2_6_44_2","first-page":"247","article-title":"Constitutive activation of STAT5 by the BCR\u2010ABL oncogene in chronic myelogenous leukemia","volume":"18","author":"Shuai K","year":"1996","journal-title":"Oncogene."},{"key":"e_1_2_6_45_2","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1182\/blood.V94.3.1108.415k07_1108_1112","article-title":"STAT5 activation by BCR\u2010Abl contributes to transformation of K562 leukemic cells","volume":"94","author":"de Groot RP","year":"1999","journal-title":"Blood."},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/16.20.6151"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207659"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.26.5.1754-1769.2006"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M000089200"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.36.22877"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-125658"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.8"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd917"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(05)03512-9"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1118"}],"container-title":["Journal of Cellular and Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1582-4934.2009.00795.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1582-4934.2009.00795.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T03:30:56Z","timestamp":1698895856000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1582-4934.2009.00795.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":54,"journal-issue":{"issue":"6b","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1111\/j.1582-4934.2009.00795.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1582-4934.2009.00795.x","archive":["Portico"],"relation":{},"ISSN":["1582-1838","1582-4934"],"issn-type":[{"value":"1582-1838","type":"print"},{"value":"1582-4934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}